<DOC>
	<DOC>NCT00393744</DOC>
	<brief_summary>The primary objective of this study is to demonstrate the non-inferiority, at the assessment visit (V3 (D10/D14)), in terms of bacteriological efficacy of pristinamycin (PRI) administered for 4 days versus amoxicillin (AMX) administered for 6 days in the treatment of tonsillitis caused by GAS, in subjects aged between 6 and 25 in the per protocol (PP) group.</brief_summary>
	<brief_title>Efficacy Study of Pristinamycin Versus Amoxicillin to Treat Tonsillitis Induced by Streptococcus in Children</brief_title>
	<detailed_description />
	<mesh_term>Tonsillitis</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<mesh_term>Pristinamycin</mesh_term>
	<criteria>subjects of both sexes aged between 6 and 25 years, weight : ≥ 20kg with suspected GASinduced tonsillitis (erythema and/or exudate of the pharynx and/or tonsils with oropharyngeal pain and/or odynophagia, fever ³ 38°C, appreciable satellite adenopathy) confirmation by positive RDT provision of throat swabs for culture ability to swallow tablets Related to the study disease: suspected viral infection (concomitant dysphonia, cough, conjunctivitis, rhinitis) adenophlegmon, peritonsillar abscesses. Related to the study treatment: known or suspected allergy to betalactamines (penicillin, cephalosporin) suspected infectious mononucleosis (increased risk of skin disorders) phenylketonuria (due to the presence of aspartame) congenital galactosaemia, glucose/galactose malabsorption syndrome, lactase deficiency (due to the presence of lactose, in powder or suspension form) allergy to pristinamycin and/or virginiamycin history of pustular rash with pristinamycin hypersensitivity or gluten intolerant (due to the presence of wheat starch) ongoing treatment with cyclosporine, methotrexate, colchicine, allopurinol, tacrolimus or oral anticoagulants. Related to previous treatment: subjects receiving antibiotic therapy in the month prior to inclusion, except for azithromycin, for which the exclusion period is 3 months. subjects on shortterm corticosteroids. Subjects on longterm corticosteroids initiated before the start of the study and taken at a controlled dosage may be included. Related to subjects: breastfeeding women women either pregnant or attempting to conceive subjects likely, during the course of the study to receive treatments prohibited by the protocol treatment with other investigational drugs in the 4 weeks prior to inclusion in the study immunodepression, clinically significant endocrine disease, cardiovascular disease, neurological disease, or any other marked diseases resulting in complications in performance of the study or interpretation of the study data known hepatic impairment known renal impairment (creatinine clearance &lt; 30 ml/minute) cancer, blood dyscrasias previous history of drug or alcohol abuse. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>